These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 28639969)

  • 1. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
    Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?
    Keohane J; O'Mahony C; O'Mahony L; O'Mahony S; Quigley EM; Shanahan F
    Am J Gastroenterol; 2010 Aug; 105(8):1788, 1789-94; quiz 1795. PubMed ID: 20389294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of Irritable Bowel Syndrome Symptoms in Quiescent Inflammatory Bowel Disease Is Associated with High Rate of Anxiety and Depression.
    Perera LP; Radigan M; Guilday C; Banerjee I; Eastwood D; Babygirija R; Massey BT
    Dig Dis Sci; 2019 Jul; 64(7):1923-1928. PubMed ID: 30725303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission.
    Jonefjäll B; Strid H; Ohman L; Svedlund J; Bergstedt A; Simren M
    Neurogastroenterol Motil; 2013 Sep; 25(9):756-e578. PubMed ID: 23731196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
    Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
    Sydora MJ; Sydora BC; Fedorak RN
    J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with longstanding ulcerative colitis in remission do not have more irritable bowel syndrome-like symptoms than controls.
    Lundgren D; Rutegård J; Eklöf V; Palmqvist R; Karling P
    BMC Gastroenterol; 2016 Nov; 16(1):139. PubMed ID: 27881072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
    Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
    Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
    Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
    Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis.
    Halpin SJ; Ford AC
    Am J Gastroenterol; 2012 Oct; 107(10):1474-82. PubMed ID: 22929759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners.
    Abdalla MI; Sandler RS; Kappelman MD; Martin CF; Chen W; Anton K; Long MD
    Inflamm Bowel Dis; 2017 Feb; 23(2):325-331. PubMed ID: 28092305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
    Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
    J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
    Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
    Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
    Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
    World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy.
    Long MD; Drossman DA
    Am J Gastroenterol; 2010 Aug; 105(8):1796-8. PubMed ID: 20686466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
    Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome.
    Campbell JP; Zierold C; Rode AM; Blocki FA; Vaughn BP
    J Clin Gastroenterol; 2021 Mar; 55(3):239-243. PubMed ID: 32324678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.